Login / Signup

Compound Heterozygous DOCK8 Mutations in a Patient with B Lymphoblastic Leukemia and EBV-Associated Diffuse Large B Cell Lymphoma.

David K BuchbinderIvan KirovJeffrey DanielsonNirali N ShahAlexandra F FreemanRishikesh S ChavanHelen C Su
Published in: Journal of clinical immunology (2019)
Mutations in Dedicator of cytokinesis 8 (DOCK8) are a rare cause of combined immunodeficiency associated with atopy, infectious susceptibility, and risk for malignancy. We describe a 22-year-old male with a diagnosis of B cell lymphoblastic leukemia followed by Epstein-Barr virus (EBV)-associated diffuse large B cell lymphoma (DLBCL) with compound heterozygous mutations in DOCK8 and normal intracellular DOCK8 protein expression. Here, B cell lymphoblastic leukemia followed by EBV-associated DLBCL led to the discovery of DOCK8 deficiency. For instances of high clinical suspicion despite normal DOCK8 protein expression, additional functional testing is critical to make a diagnosis. Understanding the spectrum of DOCK8 mutants and their phenotypes will improve our understanding of DOCK8 deficiency.
Keyphrases
  • diffuse large b cell lymphoma
  • epstein barr virus
  • acute myeloid leukemia
  • bone marrow
  • early onset
  • small molecule
  • reactive oxygen species
  • replacement therapy
  • single cell